



CIN : L22193DL2024PLC428183

ANONDITA MEDICARE LIMITED

AN ISO 9001:2015 ISO 13485:2016 & CDSCO CERTIFIED CO.

May 22, 2026

To, **Manufacturer of Condoms**
The Manager,
Listing Compliance Department
National Stock Exchange of India Limited
Exchange Plaza, Bandra Kurla Complex,
Bandra (East), Mumbai-400051

Subject: **Outcome of Board Meeting held on May 22, 2026**

SYMBOL: ANONDITA
ISIN: INE0VTV01012

Dear Sir/Madam,

Pursuant to the provisions of Regulations 30 and 33 of SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015 and such other rules and regulations, if and as may be applicable, we wish to inform you that the Board of Directors of the Company, at their meeting held today i.e., Friday May 22, 2026 at 01:00 P.M, at the corporate office situated at D-001, Sector 80, Gautam Buddha Nagar, Noida, Uttar Pradesh-201305, have, inter-alia, considered and approved the following;

1. Audited Financial Results (Standalone and Consolidated) for the half yearly and the year ended for the March 31, 2026 ("AFRs"). Enclosed are the AFRs along with the Report of the Auditors thereon;

Pursuant to Regulation 33 and 30 of the Listing Regulations and applicable LODR Regulations, if any, we are enclosing herewith the following:

1. Audited Financial Results (Standalone and Consolidated) for the half yearly and the year ended for the March 31, 2026 ("AFRs") along with the report of the Auditors thereon;
2. The declaration pursuant to Regulation 33(3) (d) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 duly signed by Chief Financial Officer of the Company;
3. Statement of deviation / Variation in utilization of Funds raised;
4. Disclosure pursuant to Related Party Transaction;

It is also hereby confirmed that the Auditors Reports issued by M/s Jain Chopra and Company, Chartered Accountants, the Statutory Auditors of the Company are with an unmodified opinion on the financial results.

The meeting of Board of Directors commenced at 01:00 P.M. and the above agendas item concluded at 08:30 P.M.

This is for your information and record, and this intimation is also being uploaded on the Company's website of the Company at the link <https://anonditamedicare.com/>.

Thanking You,
Yours Truly
For and on behalf of
Anondita Medicare Limited

Bhawna Bisht
Company Secretary and Compliance Officer
Membership No. A70843

Encl:As Above



UNIT



OFFICE



DIPPING AREA



TESTING AREA

Regd. Off.:Flat No. 704, Narmada Block N-6, Sector - D, Block - C, Vasant Kunj, New Delhi -110070

Corp Off. : D-001, Sector-80, Noida-201305, (U.P.) INDIA

Tel : 0120-4520300/1/2/3 till 99 (100 Lines) Fax : 0120-4520314

Jain Chopra & Company

Chartered Accountants

8, Chandra House, First Floor, Dr. Lane, Gole Market, New Delhi - 110001

1960, First Floor, Outram Line, Delhi - 110009

Ph. : 011-42171194 Mob : 9810247478

E-mail : jainchopra.company@gmail.com

Independent Auditor's Report

The Board of Directors

ANONDITA MEDICARE LIMITED

Opinion

We have audited the accompanying standalone financial results of **ANONDITA MEDICARE LIMITED** (the "Company") for half year ended 31st March 2026 and year to date results for the year from 1st April, 2025 to 31st March 2026 attached herewith, being submitted by the company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligation and Disclosure requirements) Regulation 2015, as amended (Listing Regulations)

In our opinion and to the best of our information and according to the explanations given to us, the aforesaid standalone financial results for the year ended March 31, 2026.

- a. Financial Results are presented in accordance with the requirements of Regulation 33 of the Listing Regulations in this regard as amended; and
- b. Gives a true and fair view in conformity with the recognition and measurement principles laid down in the applicable Accounting Standards and the accounting principles generally accepted in India, of the net profit and other financial information for the half year and the year ended 31st March, 2026.

Conclusion on Audited Standalone Financial Results for the half year and financial year ended 31 March, 2026

With respect to the Standalone Financial Results for the half year and financial year ended 31 March, 2026, based on our review conducted as stated in Auditor's Responsibilities section below, nothing has come to our attention that causes us to believe that the Standalone Financial Results for the half year and financial year ended 31 March, 2026, prepared in accordance with the recognition and measurement principles laid down in the Accounting Standards and other accounting principles generally accepted in India, has disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.



Basis of Opinion on the Audited Standalone Financial Results for the year ended 31 March, 2026

We conducted our Audit of the standalone Financial Results in accordance with the Standards on Auditing (SAs), as specified under section 143(10) of the Companies Act, 2013. Our responsibilities under those Standards are further described in the 'Auditor's Responsibilities for the Audit of the Standalone Financial Results' section of our report. We are independent of the Company in accordance with the 'Code of Ethics' issued by the Institute of Chartered Accountants of India (ICAI) together with the ethical requirements that are relevant to our audit of the standalone financial results under the provisions of the Act and the Rules made there under, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the ICAI's Code of Ethics. We believe that the audit evidence obtained by us is sufficient and appropriate to provide a basis for our audit opinion on the standalone Financial Results.

Management's Responsibilities for the Standalone Financial Results

The statement, which is the responsibility of the Company's Management and approved by the Board of Directors, has been prepared on the basis of standalone financial results. The Company's Board of Directors are responsible for the preparation and presentation of these financial results that give a true and fair view of the net profit/loss and other financial information in accordance with the applicable Accounting Standards prescribed under Section 133 of the Act read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the LODR Regulations. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the standalone financial results that give a true and fair view and are free from material misstatement, whether due to fraud or error.


In preparing the standalone financial results, the Board of Directors are responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

The Board of Directors are also responsible for overseeing the Company's financial reporting process.

Auditor's Responsibilities for the Audit of the Standalone Financial Results

Audit of the Standalone Financial Results for the year ended 31 March, 2026

Our objectives are to obtain reasonable assurance about whether the standalone financial results as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected




to influence the economic decisions of users taken on the basis of these standalone financial results.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the Annual standalone financial results, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, Under section 143(3)(i) of the Companies Act, 2013, we are also responsible for expressing our opinion on whether the company has adequate internal financial controls system in place and the operating effectiveness of such controls.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Board of Directors.
- Conclude on the appropriateness of the Board of Directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial results or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the Annual standalone annual financial results, including the disclosures, and whether the Annual standalone financial results represent the underlying transactions and events in a manner that achieves fair presentation.
- Obtain sufficient appropriate audit evidence regarding the Financial Results of the Company to express an opinion on the Financial Results.
- Materiality is the magnitude of misstatements in Annual Financial Statements that, individually or in aggregate, makes it probable that the economic decisions of reasonably knowledgeable user of Annual Standalone Financial Results may be influenced. We consider quantitative materiality and qualitative factors in (i) planning the scope of our audit work and in evaluating the results of our work; and (ii) to evaluate the effect of any identified misstatements in Financial Statements.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all



relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

Other matters

The annual financial results include the results for the half year ended 31st March, 2026 and the corresponding half year ended in the previous year being the balancing figure between the audited figures in respect of the full financial year and the published unaudited year to date figures up to the half year of the relevant financial year which were subject to limited review by us.

For Jain Chopra & Company


Chartered Accountants

FRN: 002198N

Rajesh Kumar
Rajesh Kumar

Partner

M.No.501860



UDIN:26501860HFECFW2132

Date: 22/05/2026

Place: Noida

ANONDITA MEDICARE LIMITED

(Formerly known as Anondita Healthcare)

Regd Address: Flat No.704, Narmada Block, N-6, Sector-D, Pocket-6, Vasant Kunj South West Delhi-110070

CIN:U22193DL2024PLC428183

Standalone Financial Statement as at March 31, 2026

Amount in Rs. Lakhs unless stated otherwise

Particulars	As at March 31, 2026 (Audited)	As at March 31, 2025 (Audited)
I. EQUITY AND LIABILITIES		
1. Shareholders' funds		
(a) Share Capital	1,608.66	1,329.36
(b) Reserves and surplus	9,494.38	1,430.41
(c) Money received against share warrants		
2. Share application money pending allotment		
3. Non - current liabilities		
(a) Long-term borrowings	2,359.62	1,190.76
(b) Deferred Tax Liability (net)	193.52	8.56
(c) Other Long term liabilities		
(d) Long Term Provision	17.80	9.83
4. Current liabilities		
(a) Short-term borrowings	967.80	1,548.34
(b) Trade payables		
A) Total outstanding dues of micro enterprises and small enterprises	141.23	99.37
B) Total outstanding dues of creditors other than micro enterprises and small enterprises	652.64	253.21
(c) Other current liabilities	193.85	134.74
(d) Short-term Provisions	463.62	320.06
Total	16,293.12	6,324.64
ASSETS		
1) Non Current Assets		
(a) Property, Plant and Equipment and Intangible assets		
(i) Property, Plant and Equipment	3,907.98	1,235.16
(ii) Intangible assets		
(iii) Capital Work in Progress	4,149.50	649.61
(iv) Intangible assets under development		
(b) Non-current Investments	351.58	351.58
(c) Deferred tax assets (net)		
(d) Long-term loans and advances	220.79	37.66
(e) Other non - current assets	0.16	0.24
2) Current Assets		
(a) Current investments		
(b) Inventories	1,349.14	896.28
(c) Trade receivables	3,798.80	1,660.42
(d) Cash and cash equivalents	954.10	35.56
(e) Short-term loans and advances	1,109.75	1,150.00
(f) Other current assets	451.32	308.13
Total	16,293.12	6,324.64

As per our Audit Report of even date attached

For JAIN CHOPRA & COMPANY

Chartered Accountants

FRN: 002198N

Rajesh Kumar
Rajesh Kumar
(Partner)

M.No.501860

UDIN: 26501860HFECFW2132



For & On behalf of the Board

Anondita Medicare Limited

Anupam Ghosh
Anupam Ghosh
Managing Director
DIN: 02675517

D-001 Sector -80, Noida -201305



Place: Noida

Date: 22/05/2026

ANONDITA MEDICARE LIMITED

(Formerly known as Anondita Healthcare)

Regd Address: Flat No.704, Narmada Block, N-6, Sector-D, Pocket-6, Vasant Kunj South West Delhi-110070

CIN:U22193DL2024PLC428183

Statement of Standalone Audited Financial Results for the Six Months and Year Ended March 31st, 2026

PARTICULARS	For the half year ended			For the year ended	
	As at March 31, 2026 (Audited)	As at Sept 30, 2025 (Unaudited)	As at March 31, 2025 (Audited)	As at March 31, 2026 (Audited)	As at March 31, 2025 (Audited)
I. Revenue from operations	6,404.56	4,765.06	3,554.47	11,169.62	6,051.52
II. Other Income	100.35	75.56	7.73	175.91	36.38
III. Total Income (I + II)	6,504.91	4,840.62	3,562.20	11,345.53	6,087.90
IV. Expenses:					
Cost of Materials Consumed	2,867.91	2,353.22	1,894.00	5,221.13	3,376.69
Purchase of Stock-in-Trade	-				
Change in inventories of finished goods, Work in progress and Stock in Trade	(156.25)	(186.94)	(206.53)	(343.19)	(202.97)
Employee benefit expense	391.93	271.06	259.98	662.99	483.66
Financial costs	166.95	181.32	144.36	348.27	289.46
Depreciation and amortization expense	67.09	40.03	38.83	107.12	74.65
Other expenses	1,048.63	649.21	349.54	1,697.84	605.68
Total Expenses	4,386.25	3,307.91	2,479.98	7,694.16	4,627.17
V. Profit before exceptional and extraordinary items and tax (III - IV)	2,118.66	1,532.71	1,082.22	3,651.37	1,460.73
VI. Exceptional Items					
VII. Profit before extraordinary items and tax (V - VI)	2,118.66	1,532.71	1,082.22	3,651.37	1,460.73
VIII. Extraordinary Items					
IX. Profit before tax (VII - VIII)	2,118.66	1,532.71	1,082.22	3,651.37	1,460.73
X. Tax expense:					
(1) Current tax	375.12	370.65	282.41	745.77	361.15
(2) Income tax for earlier years	38.63			38.63	
(3) Deferred tax Liability / (Assets)	169.47	15.49	(8.73)	184.96	8.57
XI. Profit(Loss) for the year from continuing operations (IX - X)	1,535.44	1,146.57	808.54	2,682.01	1,091.01
XII. Profit/(Loss) from discontinuing operations					
XIII. Tax expense of discounting operations					
XIV. Profit/(Loss) from Discontinuing operations (after tax) (XII - XIII)					
XV. Profit/(Loss) for the year (XI + XIV)	1,535.44	1,146.57	808.54	2,682.01	1,091.01
XVI. Earning per equity share:					
(1) Basic	8.49	8.14	7.18	16.65	9.70
(2) Diluted	8.49	8.14	7.18	16.65	9.70

Notes Forming Part Of The Financial Statement

As per our Audit Report of even date attached

For JAIN CHOPRA & COMPANY

Chartered Accountants

Rajesh Kumar
(Partner)

M.No.501860

UDIN: 26501860HFECFW-2132



For & On behalf of the Board
Anondita Medicare Limited

Anugam Ghosh
Managing Director
DIN: 02675517

D-001 Sector -80, Noida -201305



Place: Noida

Date: 22/05/2026

ANONDITA MEDICARE LIMITED
(Formerly known as Anondita Healthcare)

Regd Address: Flat No.704, Narmada Block, N-6, Sector-D, Pocket-6, Vasant Kunj South West Delhi-110070
CIN:U22193DL2024PLC428183

Standalone Statement of Cash Flow for the year ended March 31, 2026

Particulars	As at March 31, 2026	As at March 31, 2025
Profit before tax	3,651.37	1,460.73
Adjustments for:		
Depreciation & amortization expense	107.12	74.65
Interest expense on borrowings	348.27	289.46
Interest income	(10.65)	(3.95)
Provision for Gratuity	-	-
Preliminary exp written off	0.08	0.08
Operating Profit before working capital changes	4,096.19	1,820.96
Changes in operating assets and liabilities:		
Increase/(decrease) in trade payables	441.29	(148.09)
Increase/(decrease) in other current liabilities	59.10	43.70
Increase/(decrease) in Short Term Borrowings	(580.54)	1,101.92
Increase/(decrease) in Short Term Provisions	(319.05)	0.61
Increase/(decrease) in Long Term Provisions	7.97	4.12
Decrease/(increase) in trade receivables	(2,138.37)	(412.15)
Decrease/(increase) in Inventory	(452.86)	(186.13)
Decrease/(increase) in Short Term loans and advances	(86.76)	(372.53)
Decrease/(increase) in Long Term loans and advances	(183.13)	340.89
Decrease/(increase) in other current assets	(143.20)	(185.18)
Decrease/(increase) in other Non-current assets		
Cash generated from operations	(3,395.53)	207.16
Income taxes refunded/ (paid)	700.66	2,028.12
Net cash flow from operations (A)	(321.79)	(41.70)
Net cash flow from operations (A)	378.86	1,986.42
Cash flow from investing activities		
Purchase of /Advances for property, plant & equipment and Intangible assets	(6,279.83)	(871.59)
Sale of property, plant & equipment	-	-
Investment in Noncurrent Investment	-	(20.18)
(Increase)/Decrease in other advance	-	-
Interest received	10.65	3.95
Purchase of Fixed Assets in acquisition of Business		(1,287.83)
Purchase of Investments in acquisition of Business		(331.40)
Purchase of Advances in acquisition of Business		(101.92)
Purchase of Trade Receivable in acquisition of Business		(1,248.27)
Purchase of Inventories in acquisition of Business		(710.15)
Purchase of Other Assets in acquisition of Business		(112.60)
Purchase of Trade advances in acquisition of Business		(378.55)
Purchase of Trade Payable in acquisition of Business		500.67
Purchase of Other Liabilities in acquisition of Business		90.34
Purchase of Borrowings in acquisition of Business		2,401.29
Purchase of Deferred Tax in acquisition of Business		-
Purchase of Provisions in acquisition of Business		5.70
Purchase of Cash & Cash Equivalents in acquisition of Business		34.78
Less: Cash & Cash Equivalents		(34.76)
(Increase)/Decrease in advances to subsidiary	127.01	(698.90)
Net cash used in investing activities (B)	(6,142.17)	(2,559.43)
Cash flow from financing activities		
Proceeds from issue of capital/equity shares		734.04
Further issue of capital	479.30	142.20
Proceeds from share premium	6,470.55	910.09
Share issue expenses	(1,088.60)	(127.19)
Proceeds/(Repayment) of Long Term Borrowings	1,168.86	(1,210.52)
(Repayment)Receipt of borrowing	-	446.42
Interest paid	(348.27)	(289.48)
Net cash flow from/ (used in) financing activities (C)	6,681.84	606.68
Net increase/(decrease) in cash and cash equivalents (A+B+C)	918.53	32.65
Cash and cash equivalents at the beginning of the year	35.55	3.00
Cash and cash equivalents at the closing of the year	954.10	35.66
Cash in hand	21.86	14.29
Balances with banks:		
- On FDR	-	-
- on other than current account	610.85	10.00
- On current accounts	144.90	-
	175.49	11.28
Total	954.10	35.66

As per our Audit Report of even date attached
For JAIN CHOPRA & COMPANY
Chartered Accountants
FRN: 002198N

Rajesh Kumar
(Partner)
M.No. 501860
UDIN: 26501860 HFC



For & On behalf of the board
Anondita Medicare Limited

Anupam Ghosh
Managing Director
DIN: 02675517
D-001 Sector -80, Noida -201305




Place: Noida
Date: 22/05/2026

Notes to Financial Result

1. The above audited financial results which are published in accordance with Regulations 33 of the SEBI (Listing and Disclosure Requirements) Regulations 2015, have been reviewed by the Audit Committee and approved by the Board of Directors of the Company at their respective meeting held on 22nd May, 2026.
2. These financial results have been prepared in accordance with the recognition and measurement principle of the Accounting Standards (AS) as prescribed under section 133 of the Companies Act 2013, read with Rule 7 of (Company Accounts) Rule 2014 by the Ministry of Company Affairs as amended.
3. As per MCA notification dated 16th February 2015, Companies whose shares are listed on SME exchange as referred to in Chapter XB of SEBI (Issue of Capital and Disclosure Requirements) Regulation 2009 are exempted from compulsory requirement of adoption of Ind As
4. The Statutory Auditors of the Company have carried out "Limited Review" of the results for the half year ended on September 30, 2025.
5. Earnings per share (EPS) are not annualised except for the half year ended September 30, 2025
6. The above audited consolidated financial results of the company are posted on Company's website and website of stock exchange viz. www.nseindia.com.
7. The figures for the last half-year of the previous year ended March 31, 2025, represent the balancing figures between the audited full-year figures for March 31, 2026.
8. Provision for tax has been made as per Income Tax Act, 1961. Tax expense includes Provision for Current Tax and Provision for Deferred Tax.
9. The requirement of "AS 17 • Segment Reporting" is not applicable to the Company. The Company currently operates only in one business segment.
10. The figures for the previous year have been regrouped, reclassified, or rearranged, where necessary, to align with the current period's classification and disclosure requirements.

For JAIN CHOPRA & COMPANY
Chartered Accountants
Firm's Registration No. 002198N


Rajesh Kumar
Partner
(M. No-501860
UDIN:26501860HFECFW2132



For & On behalf of the Board
Anondita Medicare Limited


Anupam Ghosh
Managing Director
DIN: 02675517



Place: NOIDA
Dated:22/05/2026

Jain Chopra & Company

Chartered Accountants

8, Chandra House, First Floor, Dr. Lane, Gole Market, New Delhi - 110001

1960, First Floor, Outram Line, Delhi - 110009

Ph. : 011-42171194 Mob : 9810247478

E-mail : jainchopra.company@gmail.com

Independent Auditor's Report

The Board of Directors

ANONDITA MEDICARE LIMITED

Report on the Audit of Consolidated Financial Results

Opinion

We have audited the accompanying statement of consolidated financial result of **ANONDITA MEDICARE LIMITED** ("hereinafter referred to as the 'Holding Company'") its subsidiaries and associates (Holding Company, its subsidiaries and associates together referred to as "the Group"), for the half year ended March 31, 2026 and for the year ended March 31, 2026 attached herewith, being submitted by the holding company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirement) Regulations, 2015 as amended (the "Listing Regulation")

In our opinion and to the best of our information and according to the explanations given to us, the aforesaid consolidated financial statements give the information required by the Companies Act, 2013 in the manner so required and give a true and fair view in conformity with the accounting principles generally accepted in India, of the state of affairs of the Company as at March 31, 2026, and its profit, and its cash flows for the year ended on that date.

- a. Include the annual financial results of the following entities:
 1. Anondita Medicare Limited (Holding Company)
 2. Anondita Healthcare and Rubber Products India Limited (Subsidiary Company)
 3. Anondita Healthcare (Partnership Firm) (Associates)
- b. Are presented in accordance with the requirements of Regulation 33 of the LODR Regulations in this regard; and
- c. Give a true and fair view in conformity with the recognition and measurement principles laid down in the applicable accounting standards, and other accounting principles generally accepted in India, of consolidated net profit/loss and other financial information of the Group for the year ended 31st March, 2026

Conclusion on Audited Consolidated Financial Results for the half year and financial year ended 31 March, 2026

With respect to the Consolidated Financial Results for the half year and financial year ended 31st March, 2026, based on our review conducted and procedures performed as stated in Auditor's Responsibilities section below and based on the consideration of the audit conducted of the subsidiary company referred to in Other Matters section below, nothing has come to our attention that causes us to believe that the Consolidated Financial Results for the half year and financial year ended 31st March, 2026, prepared in accordance with the recognition and measurement principles laid down in the Accounting Standards and other accounting principles generally accepted in India, has disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.



Basis for Opinion on the Audited Consolidated Financial Results for the year ended 31 March, 2026

We conducted our audit in accordance with the Standards on Auditing (SAs) specified under section 143(10) of the Companies Act, 2013 (the Act). Our responsibilities under those Standards are further described in the Auditor's Responsibilities for the Audit of the Consolidated Financial Results section of our report. We are independent of the Group in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the financial statements under the provisions of the Companies Act, 2013 and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence obtained by us in terms of their reports referred to in "Other Matter" paragraph below, is sufficient and appropriate to provide a basis for our opinion.

Management's Responsibilities for the Consolidated Financial Results

This Statement, which includes the Consolidated Financial Results is the responsibility of the Parent's Board of Directors and has been approved by them for the issuance. The Consolidated Financial Results for the year ended 31 March, 2026, has been compiled from the related audited consolidated financial statements. This responsibility includes the preparation and presentation of the Consolidated Financial Results for the half year and year ended 31 March, 2026 that give a true and fair view of the consolidated net profit and other financial information of the Group in accordance with the recognition and measurement principles laid down in the Accounting Standards, prescribed under Section 133 of the Act, read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the LODR Regulations.

The respective Board of Directors of the companies included in the Group are responsible for the preparation and presentation of these consolidated financial results that give a true and fair view of the net profit/ loss and other financial information of the Group including its subsidiary and associate in accordance with the recognition and measurement principles laid down accounting principles generally accepted in India and in compliance with Regulation 33 of the LODR Regulations. The respective Board of Directors of the companies included in the Group are responsible for maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Group and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and the design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring accuracy and completeness of the accounting records, relevant to the preparation and presentation of the consolidated financial results that give a true and fair view and are free from material misstatement, whether due to fraud or error, which have been used for the purpose of preparation of the consolidated financial results by the Directors of the Holding Company, as aforesaid.

In preparing the consolidated financial results, the respective Board of Directors of the companies included in the Group are responsible for assessing the ability of the Group to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the respective Board of Directors either intends to liquidate the Group or to cease operations, or has no realistic alternative but to do so.

The respective Board of Directors of the companies included in the Group are responsible for overseeing the financial reporting process of the Group.

Auditor's Responsibilities

Auditor's Responsibilities for the Audit of the Consolidated Financial Results

Our objectives are to obtain reasonable assurance about whether the consolidated financial results for the year ended 31 March, 2026 as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and



are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these consolidated financial results.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the consolidated financial results, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the company's internal control.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Board of Directors.
- Conclude on the appropriateness of the Board of Directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the ability of the Group to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the consolidated financial results or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Group to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the consolidated financial results, including the disclosures, and whether the consolidated financial results represent the underlying transactions and events in a manner that achieves fair presentation.
- Obtain sufficient appropriate audit evidence regarding the Annual financial results/financial information of the entities within the Group to express an opinion on the Consolidated Financial Results. We are responsible for the direction, supervision and performance of the audit of financial information of such entities included in the consolidated financial results of which we are the independent auditors. For the other entities included in the Consolidated Financial Results, which have been audited by other auditor such other auditor remain responsible for the direction, supervision and performance of the audits carried out by them. We remain solely responsible for our audit opinion.

Materiality is the magnitude of misstatements in the Consolidated Financial Results that, individually or in aggregate, makes it probable that the economic decisions of a reasonably knowledgeable user of the Consolidated Financial Results may be influenced. We consider quantitative materiality and qualitative factors in (i) planning the scope of our audit work and in evaluating the results of our work; and (ii) to evaluate the effect of any identified misstatements in the Consolidated Financial Results.

We communicate with those charged with governance of the Holding Company and such other entities included in the consolidated financial results of which we are the independent auditors regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33(8) of the LODR Regulations, as amended, to the extent applicable.

The Statement includes the results of the entities as listed under paragraph (a)(i) of Opinion and Conclusion section above.



We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33(8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.

Other Matters

The Statement includes the results for the half year ended 31 March, 2026 being the balancing figure between audited figures in respect of the full financial year and the published year to date figures up to the half year of the current financial year which were subject to limited review by us. Our report is not modified in respect of this matter.

The Consolidated Financial Results include the audited financial results of 01 subsidiary and 01 associate. The consolidated financial results reflect total revenue of ₹36.79 crore and net profit after tax of ₹7.45 crore for the year ended March 31, 2026 and for the period from 01st April, 2025 to 31st March, 2026 respectively, as considered in the Consolidated Financial Results, which have not been audited by us. The financial statements present a true and fair view of the state of affairs of the Group, including its business operations, financial position, and its profit and loss for the period under consideration. They have been prepared in accordance with the applicable accounting standards and relevant statutory requirements. The financial information is complete, consistent, and free from material misstatement, and reflects the underlying transactions and events in a fair and transparent manner.

Our opinion on the Consolidated Financial Results is not modified in respect of the above matters with respect to our reliance on the work done.

For Jain Chopra & Company
Chartered Accountants

FRN: 002198N


Rajesh Kumar

Partner

M.No.501860



UDIN: 265018600JUIWG8370

Date: 22/05/2026

Place: Noida.

ANONDITA MEDICARE LIMITED
(Formerly known as Anondita Healthcare)

Regd Address: Flat No.704, Narmađa Block, N-6, Sector-D, Pocket-6, Vasant Kunj South West Delhi-110070
CIN:U22193DL2024PLC42B183

Consolidated Financial Statement as at March 31, 2026

Amount in Rs. Lakhs unless stated otherwise

Particulars	As at March 31, 2026	As at March 31, 2025
I. EQUITY AND LIABILITIES		
1. Shareholders' funds		
(a) Share Capital	1,808.66	1,329.36
(b) Reserves and surplus	11,114.92	2,380.36
(c) Minority Interest	203.34	118.16
(d) Money received against share warrants	-	-
2. Share application money pending allotment	-	-
3. Non - current liabilities		
(a) Long-term borrowings	2,387.03	1,190.76
(b) Deferred Tax Liability (net)	193.52	8.56
(c) Other Long term liabilities	-	-
(d) Long Term Provision	17.80	9.83
4. Current liabilities		
(a) Short-term borrowings	973.12	1,548.34
(b) Trade payables	-	-
A) Total outstanding dues of micro enterprises and small enterprises	141.23	123.88
B) Total outstanding dues of creditors other than micro enterprises and small enterprises	661.56	257.65
(c) Other current liabilities	248.79	210.06
(d) Short-term Provisions	733.14	512.17
Total	18,483.12	7,689.13
ASSETS		
1) Non Current Assets		
(a) Property, Plant and Equipment and Intangible assets		
(i) Property, Plant and Equipment	3,909.76	1,237.04
(ii) Intangible assets		
(a) Goodwill	19.18	19.18
(iii) Capital Work In Progress	4,149.50	649.61
(iv) Intangible assets under development	-	-
(b) Non-current Investments	331.40	331.40
(c) Deferred tax assets (net)	0.24	0.22
(d) Long-term loans and advances	220.79	37.67
(e) Other non - current assets	0.16	0.28
2) Current Assets		
(a) Current investments	-	-
(b) Inventories	2,075.01	1,349.86
(c) Trade receivables	5,185.67	2,675.33
(d) Cash and Bank balance	965.19	42.94
(e) Short-term loans and advances	1,114.56	950.60
(f) Other current assets	511.66	395.00
Total	18,483.12	7,689.13

Notes: As attached
As per our Audit Report of even date attached
For JAIN CHOPRA & COMPANY
Chartered Accountants
FRN: 002198N


Rajesh Kumar
(Partner)
M.No.501860



UDIN: 26501860JUIWG8370

Place: NOIDA
Date: 22/05/2026

For & On behalf of the Board
Anondita Medicare Limited



Anupam Ghosh
Managing Director
DIN: 02675517

D-001 Sector -80, Noida -201305

ANONDATA MEDICARE LIMITED

Regd Address: Flat No.704, Narmada Block, N-6, Sector-D, Pocket-6, Vasant Kunj South West Delhi-110070
CIN:U22193DL2024PLC428183

Statement of Consolidated Financial Results for the six months and Year ended March 31,2026
Amount in Rs. Lakhs unless stated otherwise

PARTICULARS	For the Half Year Ended			For the Year ended	
	As at March 31st, 2026 (Audited)	As at Sept 30th, 2025 (Unaudited)	As at March 31st, 2025 (Audited)	As at March 31st, 2026 (Audited)	As at March 31st, 2025 (Audited)
I. Revenue from operations	8,331.87	5,409.70	4,558.57	13,741.57	7,699.07
II. Other Income	43.46	40.78	3.61	84.24	13.88
III. Total Income (I + II)	8,375.33	5,450.48	4,562.18	13,825.81	7,712.95
IV. Expenses:			1,894.00	5,221.13	3,376.69
Cost of Materials Consumed	2,867.91	2,353.22	743.80	1,384.54	744.86
Purchase of Stock-in-Trade	1,199.61	164.93			
Change in inventories of finished goods, Work in progress and Stock in Trade	(500.33)	(79.18)	(420.57)	(579.51)	(293.20)
Employee benefit expense	484.75	348.10	424.94	832.85	686.80
Financial costs	171.45	182.35	145.78	353.80	291.09
Depreciation and amortization expense	67.21	40.87	39.52	108.09	75.79
Other expenses	1,133.47	702.49	323.68	1,835.95	618.70
Total Expenses	5,424.07	3,712.78	3,151.13	9,136.85	5,500.73
V. Profit before exceptional and extraordinary items and tax (III - IV)	2,951.26	1,737.70	1,411.05	4,688.96	2,212.22
VI. Exceptional Items					
VII. Profit before extraordinary items and tax (V - VI)	2,951.26	1,737.70	1,411.05	4,688.96	2,212.22
VIII. Extraordinary Items					
IX. Profit before tax (VII - VIII)	2,951.26	1,737.70	1,411.05	4,688.96	2,212.22
X. Tax expense					
(1) Current tax	594.87	420.42	372.38	1,015.29	553.25
(2) Income Tax for Earlier years	59.08	-		59.08	
(3) Deferred tax Liability / (Assets)	169.45	15.49	(8.80)	184.94	8.50
XI. Profit/(Loss) for the year from continuing operations (IX - X)	2,127.86	1,301.79	1,047.47	3,429.65	1,650.47
XII. Profit/(Loss) from discontinuing operations					
XIII. Tax expense of discounting operations					
XIV. Profit/(Loss) from Discontinuing operations (after tax) (XII - XIII)					
XV. Profit/(Loss) for the year (XI + XIV)	2,127.86	1,301.79	1,047.47	3,429.65	1,650.47
Profit for the Year attributable to					
a. Owners of the Company	1,894.46	1,159.00	1,018.53	3,344.60	1,588.21
b. Minority Interest	233.40	142.79	28.95	85.05	62.26
XVI. Earning per equity share:					
(1) Basic	11.76	9.12	9.31	21.30	14.67
(2) Diluted	11.76	9.12	9.31	21.30	14.67

Notes: As attached

As per our Audit Report of even date attached

For JAIN CHOPRA & COMPANY

Chartered Accountants

FRN: 002196N

Rajesh Kumar
Rajesh Kumar
(Partner)
M.No.501860



UDIN: 265018600JUIWG8370


Place: NOIDA

Date: 22/05/2026

For & On behalf of the Board

Anondita Medicare Limited

Anupam Ghosh
Anupam Ghosh
Managing Director
DIN: 02675517



D-001 Sector -80, Noida -201305

ANONDITA MEDICARE LIMITED
(Formerly known as Anondita Healthcare)

Regd Address: Flat No.704, Namada Block, N-6, Sector-D, Pocket-6, Vasant Kunj South West Delhi-110070
CIN:U22193DL2024PLC428183

Consolidated Statement of Cash Flow for the year ended March 31, 2026


Particulars	As at March 31, 2026	As at March 31, 2025
Profit before tax	4,688.96	2,212.22
Adjustments for:		
Depreciation & amortization expense	108.09	75.79
Interest expense on borrowings	353.80	320.74
Interest income	(10.65)	(3.95)
Loss on sale of Car	-	0.86
Provision for Gratuity	-	-
Preliminary exp written off	0.12	0.12
Operating Profit before working capital changes	5,140.32	2,806.78
Changes in operating assets and liabilities:		
Increase/(decrease) in trade payables	421.26	(484.82)
Increase/(decrease) in other current liabilities	38.72	(117.09)
Increase/(decrease) in Short Term Provisions	(511.16)	0.61
Increase/(decrease) in Long Term Provisions	7.97	4.12
Decrease/(increase) in trade receivables	(2,510.34)	(1,113.82)
Decrease/(increase) in Inventory	(717.00)	(276.37)
Decrease/(increase) in Short Term loans and advances	(163.95)	(1,456.43)
Decrease/(increase) in Long Term loans and advances	(183.13)	340.89
Decrease/(increase) in other current assets	(116.86)	(199.18)
Decrease/(increase) in other Non-current assets		
	(3,734.27)	(3,302.09)
Cash generated from operations	1,406.05	(896.31)
Income taxes refunded/ (paid)	(342.24)	(44.10)
Net cash flow from operations (A)	1,063.81	(740)
Cash flow from investing activities		
Purchase of /Advances for property, plant & equipment and Intangible assets	(6,280.69)	(673.90)
Sale of property, plant & equipment		4.23
Investment in Noncurrent Investment		(20.18)
(Increase)/Decrease in other advance		-
Interest received	10.65	3.95
		(1,287.83)
Purchase of Fixed Assets in acquisition of Business		(331.40)
Purchase of Investments in acquisition of Business		(101.92)
Purchase of Advances in acquisition of Business		(1,248.27)
Purchase of Trade Receivable in acquisition of Business		(710.15)
Purchase of Inventories in acquisition of Business		(112.60)
Purchase of Other Assets in acquisition of Business		(378.55)
Purchase of Trade advances in acquisition of Business		500.67
Purchase of Trade Payable in acquisition of Business		90.34
Purchase of Other Liabilities in acquisition of Business		2,401.29
Purchase of Borrowings in acquisition of Business		-
Purchase of Deferred Tax in acquisition of Business		5.70
Purchase of Provisions in acquisition of Business		(26.72)
Purchase of Cash & Cash Equivalents in acquisition of Business		26.72
Less: Cash & Cash Equivalents		
	(6,270.04)	(1,858.60)
Cash flow from financing activities		
Proceeds from issue of capital/equity shares		734.16
Further issue of Capital	479.30	142.20
Share Premium	6,470.55	1,464.36
Share Issue Expense	(1,088.60)	(192.11)
Proceeds/(Repayment) of Long Term Borrowings	1,195.27	(1,210.52)
Increase/(decrease) in Short Term Borrowings	(575.22)	1,530.91
(Repayment)/Receipt of borrowing		446.42
Interest paid	(353.80)	(320.74)
Net cash flow from/ (used in) financing activities (C)	6,128.50	2,594.68
Net increase/(decrease) in cash and cash equivalents (A+B+C)	922.27	(4.33)
Cash and cash equivalents at the beginning of the year	42.94	47.27
Cash and cash equivalents at the closing of the year	965.21	42.94
Cash in hand	25.26	18.14
Balances with banks:		
- On FDR	900.11	10.00
- on other than current account	155.64	-
- On current accounts	184.20	14.80
Total	965.21	42.94

Notes: As attached

As per our Audit Report of even date attached

For JAIN CHOPRA & COMPANY
Chartered Accountants
FRN: 002198N

Rajesh Kumar
(Partner)
M.No.501880




UDIN: 265018600JUIWG8370

Place: NOIDA
Date: 22/05/2026

For & On behalf of the Board

Anondita Medicare Limited

Anupam Ghosh
Managing Director
DIN: 02675517



D-001 Sector -80, Noida -201305

Notes to Financial Result

1. The above audited financial results which are published in accordance with Regulations 33 of the SEBI (Listing and Disclosure Requirements) Regulations 2015, have been reviewed by the Audit Committee and approved by the Board of Directors of the Company at their respective meeting held on 22nd May, 2026.
2. These financial results have been prepared in accordance with the recognition and measurement principle of the Accounting Standards (AS) as prescribed under section 133 of the Companies Act 2013, read with Rule 7 of (Company Accounts) Rule 2014 by the Ministry of Company Affairs as amended.
3. As per MCA notification dated 16th February 2015, Companies whose shares are listed on SME exchange as referred to in Chapter XB of SEBI (Issue of Capital and Disclosure Requirements) Regulation 2009 are exempted from compulsory requirement of adoption of Ind As
4. The Statutory Auditors of the Company have carried out "Limited Review" of the results for the half year ended on September 30, 2025.
5. Earnings per share (EPS) are not annualised except for the half year ended September 30, 2025
6. The above audited consolidated financial results of the company are posted on Company's website and website of stock exchange viz. www.nseindia.com.
7. The figures for the last half-year of the previous year ended March 31, 2025, represent the balancing figures between the audited full-year figures for March 31, 2026.
8. Provision for tax has been made as per Income Tax Act, 1961. Tax expense includes Provision for Current Tax and Provision for Deferred Tax.
9. The requirement of "AS 17 • Segment Reporting" is not applicable to the Company. The Company currently operates only in one business segment.
10. The figures for the previous year have been regrouped, reclassified, or rearranged, where necessary, to align with the current period's classification and disclosure requirements.

Notes: As attached
As per our Audit Report of even date attached
For JAIN CHOPRA & COMPANY
Chartered Accountants
FRN: 002198N



Rajesh Kumar
(Partner)
M.No.501860



UDIN: 265018600JUIWG8370

Place: NOIDA
Date: 22/05/2026

For & On behalf of the Board
Anondita Medicare Limited


Anupam Ghosh
Managing Director
DIN: 02675517



D-001 Sector -80, Noida -201305



ANONDITA MEDICARE LIMITED

AN ISO 9001:2015 ISO 13485:2016 & CDS CO CERTIFIED CO.
Manufacturer of Condoms

May 22, 2026

To,
 The Manager,
 Listing Compliance Department
National Stock Exchange of India Limited
 Exchange Plaza, Bandra Kurla Complex,
 Bandra (East), Mumbai-400051

Subject: Statement of deviation or variation in the use of proceeds of Initial Public Offering under Regulation 32 of SEBI (LODR) Regulations, 2015.

SYMBOL: ANONDITA
 ISIN: INE0VTV01012

Dear Sir/Madam,

Pursuant to Regulation 32 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 and SEBI Circular No. CIR/CFD/CMD1/162/2019 dated December 24, 2019, please note that there are no deviation(s) or variation(s) in respect of the utilization of the proceeds of the Initial Public Offer ("IPO") of the Company during the half year ended March 31, 2026 as mentioned in the object clause of the Prospectus dated August 28, 2025.

Please find enclosed herewith the Statement of Deviation(s) or Variation(s) in the utilisation of funds raised through the Initial Public Offering ("IPO") of the Company for the half year ended March 31, 2026.

The above information is also being uploaded on the website of the Company <https://anonditamedicare.com/>.

Kindly take the above information on your records.

For and on behalf of
 Anondita Medicare Limited

Bhawna Bisht
 Company Secretary and Compliance officer
 Membership No. A70843



UNIT



OFFICE



DIPPING AREA



TESTING AREA

Regd. Off.: Flat No. 704, Narmada Block N-6, Sector - D, Block - C, Vasant Kunj, New Delhi -110070
 Corp Off. : D-001, Sector-80, Noida-201305, (U.P.) INDIA



ANONDITA MEDICARE LIMITED

AN ISO 9001:2015 ISO 13485:2016 & CDSCO CERTIFIED CO.

Manufacturer of Condoms

	<ul style="list-style-type: none"> The allocation towards General Corporate Purposes and Unidentified Acquisition was revised from ₹2015.87 Lakhs to ₹1737.46 Lakhs and shall now be utilized only towards General Corporate Purposes within the revised regulatory limits. No unidentified acquisition shall be undertaken using the IPO proceeds. The Company has also revised the deployment timeline of funds under General Corporate Purposes. The entire balance amount was originally expected to be utilized within FY 2025–26; however, the remaining balance of Rs. 123.25 Lakhs shall now be utilized during FY 2026–27. Further, the utilization towards working capital requirements increased due to expansion in the scale of operations and higher working capital needs. The original estimates were based on a projected turnover of ₹10,000 Lakhs for FY 2025–26, which was revised to approximately ₹14,500 Lakhs. There is no material variation in the Capital Expenditure object except changes and/or additions to vendors, as disclosed in the Prospectus.
Comments of the Audit Committee after review	Not Applicable(NA)
Comments of the auditors, if any	Not Applicable(NA)

Objects for which funds have been raised and where there has been a deviation, in the following table

Original Object	Modified Object, if any	Original Allocation (in Lakhs)	Modified allocation, if any (in Lakhs)	Funds Utilised (in Lakhs)	Amount of Deviation/ Variation for the quarter according to applicable	Remarks if any





ANONDITA MEDICARE LIMITED

AN ISO 9001:2015 ISO 13485:2016 & CDSCO CERTIFIED CO.

Manufacturer of Condoms

			Lakhs)		according to applicable object(in Lakhs)	
Capex	No variation in object of the issue except changes and/or additions to vendors, as disclosed in the Prospectus	600	No Change	262.10	NA	NA
Funding Working Capital Requirements	<p>Due to revision in GCP limits (from 35% to 25%) under the revised SEBI guidelines, an amount of Allocation of Rs. 278.41 Lacs out of Object 3 (i.e., General Corporate Purposes) towards funding the Company's working capital requirements, including working capital loans and Cash Credit (CC) limits and with this reallocation, the revised total allocation for working capital now stands at Rs. 3,778.41 Lacs.</p> <p>Furthermore, utilization under this object has exceeded the originally estimated utilization during financial year 2025-26 and 2026-27 due to the Company's expanded scale of operations and higher working capital requirements and the working capital estimates were initially based on a projected turnover of ₹100 crore for FY 2025-26, which has now been revised to approximately ₹145 crore.</p>	3500	3778.41	3575.55	NA	NA
General Corporate	Due to revision in GCP limits (from 35% to 25%) under the revised SEBI guidelines, the funds	2015.87	1737.46	1614.21	NA	NA



UNIT



OFFICE



DIPPING AREA



TESTING AREA

Regd. Off.: Flat No. 704, Narmada Block N-6, Sector - D, Block - C, Vasant Kunj, New Delhi -110070

Corp Off. : D-001, Sector-80, Noida-201305, (U.P.) INDIA

Tel : 0120-4520200/41212411/00 (400 Lines) F : 0120-4520200



ANONDITA MEDICARE LIMITED

AN ISO 9001:2015 ISO 13485:2016 & CDSCO CERTIFIED CO.

Manufacturer of Condoms

<p>(GCP) 1. f or Unidenti ed Acquisitio n 2. For GCP (Capped at 25% of gross issue size)</p>	<p>Object 3 (Unidentified Acquisition and General Corporate Purposes) will be utilized for GCP only, now restricted to 25% of the total IPO proceeds. Any amount excess of GCP Limit will be transferred towards meeting the Company's working capital requirements.</p> <p>No unidentified acquisition will be undertaken using the IPO proceeds.</p> <p>Furthermore, the allocation of Rs. 278.41 Lacs from Object 3 to Object 2 for funding the Company's working capital requirements, including working capital loans and Cash Credit Limit. With this reallocation, the revised total allocation for General Corporate Purposes stands at Rs. 1,737.46 Lacs.</p> <p>Further, while the utilization of these funds was initially projected over FY 2025-26 and FY 2026-27, it was subsequently expected that the entire allocation would be deployed within FY 2025-26. However, the balance amount shall now be utilized during the current financial year 2026-27.</p>					
<p>Issue Related Expenses</p>	<p>NA.</p>	<p>833.13</p>	<p>-</p>	<p>824.01</p>	<p>NA</p>	<p>NA</p>

For and on behalf of
Anondita Medicare Limited

Anupam Ghosh
Managing Director
DIN: - 02675517

Address: D-001, Sector 80, Gautam Buddha Nagar,
Noida, Uttar Pradesh-201305

DATE : MAY 22, 2026



UNIT



OFFICE



DIPPING AREA



TESTING AREA

Regd. Off.: Flat No. 704, Narmada Block N-6, Sector - D, Block - C, Vasant Kunj, New Delhi -110070
Corp Off. : D-001, Sector-80, Noida-201305, (U.P.) INDIA

Tel : 0120 4520200/4202400/4202500



CIN : L22193DL2024PLC428183

ANONDITA MEDICARE LIMITED

AN ISO 9001:2015 ISO 13485:2016 & CDSO CERTIFIED CO.
Manufacturer of Condoms

May 22, 2026

To,
The Manager,
Listing Compliance Department
National Stock Exchange of India Limited
Exchange Plaza, Bandra Kurla Complex,
Bandra (East), Mumbai-400051

Subject: Declaration with respect to Auditor's Reports with unmodified opinion for the Annual Audited Financial Results (Standalone and Consolidated) for the financial year ended March 31, 2026 pursuant to Regulation 33(3)(d) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

SYMBOL: ANONDITA
ISIN: INE0VTV01012

Dear Sir/Madam,

In pursuant to the Regulation 33(3)(d) of SEBI (Listing Obligations and Disclosure Requirement) Regulations, 2015 read with SEBI circular no. CIRC/CFD/CMD/56/2016 dated May 27, 2016, we hereby declare and confirm that M/s Jain Chopra and Company, (FRN: 002198N) Statutory Auditors of the Company, have issued Auditor's Reports with Unmodified Opinion on Audited Financial Results of the Company (Standalone and consolidated) for the half-year and financial year ended March 31, 2026.

The financial results have been reviewed by the Audit Committee and approved by the Board of Directors at its meeting held on May 22, 2026. Kindly take note of the same in your records.

This is for your information and record.

Thanking You,
Yours Truly
For and on behalf of
Anondita Medicare Limited



Sunita Naithani
Chief Financial Officer (CFO)



UNIT



OFFICE



DIPPING AREA



TESTING AREA

Regd. Off.: Flat No. 704, Narmada Block N-6, Sector - D, Block - C, Vasant Kunj, New Delhi -110070
Corp Off. : D-001, Sector-80, Noida-201305, (U.P.) INDIA
Tel : 0120-452000/1000 (10 lines)

Format for Disclosure of Related Party Transactions (applicable only for half-yearly filings i.e., 2nd and 4th quarter)

Format for Disclosure of Related Party Transactions (applicable only for half-yearly filings i.e., 2nd and 4th quarter)														Additional disclosure	
Sr. No.	Details of the party (listed entity /subsidiary) entering into the transaction		Details of the counterparty			Type of related party transaction	Details of other related party transaction	Value of the related party transaction as approved by the audit committee	Remarks on approval by audit committee	Value of the related party transaction ratified by the audit committee	Date of Audit Committee Meeting where the ratification was approved	Value of transaction during the reporting period	In case monies are due to either party as a result of the transaction		In case any financials
	Name	PAN	Name	PAN	Relationship of the counterparty with the listed entity or its subsidiary								Opening balance	Closing balance	
<input type="button" value="Add"/> <input type="button" value="Delete"/>															
1	Anondita Medicare Limited	ABACA3332M	Anondita Healthcare Products Private Limited	AANCA1209M	ENTITY UNDER COMMON CONTROL PROMOTER	Any other transaction	Renting on Property	99.12	NA			99.12	15.86	0.00	
2	Anondita Medicare Limited	ABACA3332M	Anondita Healthcare Products Private Limited	AANCA1209M	ENTITY UNDER COMMON CONTROL PROMOTER	Any other transaction	Security Deposit on Rental Property		NA			0.00	19.50	19.50	
3	Anondita Medicare Limited	ABACA3332M	Anondita Healthcare & Rubber Products India Limited	AAVCA587G	SUBSIDIARY COMPANY	Sale of goods or services		600.53	NA			600.53	324.06	332.47	
4	Anondita Medicare Limited	ABACA3332M	Anondita Healthcare & Rubber Products India Limited	AAVCA587G	SUBSIDIARY COMPANY	Loan		442.50	NA			442.50	1579.09	571.89	
5	Anondita Medicare Limited	ABACA3332M	Anondita Healthcare & Rubber Products India Limited	AAVCA587G	SUBSIDIARY COMPANY	Loan		1518.88	NA			1518.88	0.00	0.00	
6	Anondita Medicare Limited	ABACA3332M	Anondita Healthcare & Rubber Products India Limited	AAVCA587G	SUBSIDIARY COMPANY	Interest received		69.19	NA			69.19	0.00	0.00	
7	Anondita Medicare Limited	ABACA3332M	Anondita Healthcare (PARTNERSHIP FIRM)	ABXFA1571G	ENTITY UNDER COMMON CONTROL PROMOTER	Any other transaction	Car Rental Services	88.50	NA			88.50	14.50	0.00	
8	Anondita Medicare Limited	ABACA3332M	Anondita Latex Private Limited	AAMCA5889J	ENTITY UNDER COMMON CONTROL PROMOTER	Advance			NA			0.00	31.66	31.66	
9	Anondita Medicare Limited	ABACA3332M	Anondita Latex Private Limited	AAMCA5889J	ENTITY UNDER COMMON CONTROL PROMOTER	Sale of goods or services			NA			0.00	3.25	3.25	
10	Anondita Medicare Limited	ABACA3332M	Anondita Healthcare Products Private Limited	AANCA1209M	ENTITY UNDER COMMON CONTROL PROMOTER	Any other transaction	Corporate Guarantee Received	374.00	NA			374.00	0.00	373.06	
11	Anondita Medicare Limited	ABACA3332M	Anupam Ghosh	AEQPG6875G	ENTITY UNDER COMMON CONTROL PROMOTER	Any other transaction	Personal Guarantee Received	400.00	NA			400.00	0.00	400.00	
12	Anondita Medicare Limited	ABACA3332M	Anondita Healthcare Products Private Limited	AANCA1209M	ENTITY UNDER COMMON CONTROL PROMOTER	Any other transaction	Loan Guarantee Fees	4.41	NA			4.41	0.00	0.00	
13	Anondita Medicare Limited	ABACA3332M	Anondita Healthcare	ABXFA1571G	ENTITY UNDER COMMON CONTROL PROMOTER	Any other transaction	Security Deposit for Car Rental Service		NA			0.00	25.00	25.00	
Total value of transaction during the reporting period												3597.13			

